Range Impact (RNGE) 10-Q5 Nov 132014 Q2 Quarterly reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
Document And Entity Information	Sep. 30, 2013	Nov. 01, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'Stevia First Corp.	'
Entity Central Index Key	'0001438943	'
Current Fiscal Year End Date	'--03-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	60,495,280
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Sep. 30, 2013	Mar. 31, 2013
Current Assets	'	'
Cash	$551,318	$392,483
Security deposit	2,500	2,500
Prepaid expenses	10,473	9,073
Current portion of advance payment on related party lease	72,917	125,000
Total Current Assets	637,208	529,056
Advance payment on related party lease, net of current portion	0	10,417
Total Assets	637,208	539,473
Current Liabilities	'	'
Accounts payable and accrued liabilities	111,173	112,263
Accounts payable - Related Party	2,611	6,930
Accrued interest	9,375	9,375
Derivative liability	1,369,517	398,603
Total Current Liabilities	1,492,676	527,171
Convertible Notes Payable	762,500	955,000
Less discount	-158,254	-374,592
Convertible notes payable, net of discount	604,246	580,408
Total liabilities	2,096,922	1,107,579
Stockholders' Deficit	'	'
Common stock, par value $0.001 per share; 525,000,000 shares authorized; 59,884,168 and 55,659,102 shares issued and outstanding	59,884	55,659
Unvested, issued common stock	-165,471	-157,500
Additional paid-in-capital	4,500,895	3,707,772
Deficit accumulated during the development stage	-5,855,022	-4,174,037
Total stockholders' deficit	-1,459,714	-568,106
Total liabilities and stockholders' deficit	$637,208	$539,473

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	525,000,000	525,000,000
Common stock, shares issued	59,884,168	55,659,102
Common stock, shares outstanding	59,884,168	55,659,102

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended		75 Months Ended
CONDENSED STATEMENTS OF OPERATIONS (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Revenue	$0	$0	$0	$0	$0
Operating expenses:	'	'	'	'	'
General and administrative	701,318	797,939	1,427,514	1,083,586	4,958,430
Rent and other related party costs	31,950	39,517	73,100	66,450	241,350
Research and development	100,156	0	223,395	89,090	478,117
Total operating expenses	833,424	837,456	1,724,009	1,239,126	5,677,897
Loss from operations	-833,424	-837,456	-1,724,009	-1,239,126	-5,677,897
Other income (expenses)	'	'	'	'	'
Interest expense	-41,346	-28,016	-235,087	-52,953	-606,072
Change in fair value of derivative liability	93,090	0	278,111	0	402,966
Cost of Offering	0	0	0	0	-78,458
Gain on settlement of debt	0	0	0	107,004	107,004
Foreign currency translation	0	-301	0	-202	-2,565
Net loss	($781,680)	($865,773)	($1,680,985)	($1,185,277)	($5,855,022)
Loss per share - basic and diluted (in dollars per share)	($0.01)	($0.02)	($0.03)	($0.02)	'
Weighted average number of common shares outstanding- basic and diluted (in shares)	59,784,168	52,625,421	57,898,055	52,291,978	'

CONDENSED_STATEMENTS_OF_STOCKH

CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Unvested Issued Common Stock [Member]	Deficit Accumulated During the Development Stage [Member]
Balance, amount at Mar. 31, 2013	($568,106)	$55,659	$3,707,772	($157,500)	($4,174,037)
Balance, shares at Mar. 31, 2013	'	55,659,102	'	'	'
Sale of common stock and warrants at $0.34 per unit, net of derivative value of warrants, value	-115,775	3,676	-119,451	0	0
Sale of common stock and warrants at $0.34 per unit, net of derivative value of warrants, shares	'	3,676,472	'	'	'
Common stock issued upon conversion of notes payable, value	192,500	428	192,072	0	0
Common stock issued upon conversion of notes payable, shares	'	427,778	'	'	'
Common stock issued to employees and director unvested, value	28,029	100	35,900	-7,971	0
Common stock issued to employees and director unvested, shares	'	100,000	'	'	'
Common stock issued as payment of accrued interest, value	18,750	21	18,729	0	0
Common stock issued as payment of accrued interest, shares	'	20,816	'	'	'
Stock based compensation	665,873	0	665,873	0	0
Net Loss	-1,680,985	0	0	0	-1,680,985
Balance, amount at Sep. 30, 2013	($1,459,714)	$59,884	$4,500,895	($165,471)	($5,855,022)
Balance, shares at Sep. 30, 2013	'	59,884,168	'	'	'

CONDENSED_STATEMENTS_OF_STOCKH1

CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) (USD $)	6 Months Ended
	Sep. 30, 2013
Per unit sale of common stock and warrants	$0.34

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended		75 Months Ended
CONDENSED STATEMENTS OF CASH FLOWS (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Operating activities	'	'	'
Net loss	($1,680,985)	($1,185,277)	($5,855,022)
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
expenses paid on behalf of the Company by third party	0	0	5,000
Stock based compensation	693,902	581,923	2,506,925
Gain on settlement of debt	0	-107,004	-107,004
Financing cost	0	0	78,458
Change in fair value of derivative liability	-278,111	0	-402,966
Amortization of debt discount	216,338	29,567	519,150
Cancellation of fees applied to option exercise price	0	0	196,000
Prepaid expenses	-1,400	-95,386	-10,473
Advance payment on related party lease	62,500	-197,917	-72,917
Accrued interest	18,750	11,311	74,833
Accounts payable - related party	-4,319	-8,493	2,611
Accounts payable and accrued liabilities	-1,090	88,560	106,173
Net cash used in operating activities	-974,415	-882,716	-2,959,232
Financing activities	'	'	'
Proceeds from issuance of promissory notes	0	425,000	196,800
Proceeds from issuance of convertible notes, net	0	0	1,320,000
Proceeds from exercise of options	0	35,000	213,000
Proceeds from sale of common stock, net	1,133,250	425,000	1,783,250
Net cash provided by financing activities	1,133,250	885,000	3,513,050
Investing activities	'	'	'
Security deposit	0	0	-2,500
Net cash used in investing activities	0	0	-2,500
Net increase in cash	158,835	1,284	551,318
Cash and cash equivalent - beginning of period	392,483	532,206	0
Cash and cash equivalent - end of period	551,318	533,490	551,318
Cash paid during the period for:	'	'	'
Interest	12,075	0	12,075
Income taxes	0	0	0
Non-cash activities:	'	'	'
Fair value of warrants issued with common stock recorded as derivative liability	1,249,025	0	1,249,025
Cancellation of accounts payable applied to option exercise price	0	140,000	140,000
Issuance of common stock upon conversion of convertible and promissory notes payable and accrued interest	211,250	107,004	767,754
Fair value of beneficial conversion feature of convertible notes	0	0	177,404
Fair value of warrants issued with convertible debentures, recognized as a note	0	0	500,000
Loan (expenses paid on behalf of Company by third party)	$0	$0	($5,000)

BUSINESS_AND_BASIS_OF_OPERATIO

BUSINESS AND BASIS OF OPERATIONS	6 Months Ended
BUSINESS AND BASIS OF OPERATIONS	Sep. 30, 2013
Nature and Continuance Of Operation [Abstract]	'
BUSINESS AND BASIS OF OPERATIONS	'
	1. BUSINESS AND BASIS OF OPERATIONS

	Stevia First Corp. (the “Company”, “we”, “us” or “our”), was incorporated under the laws of the State of Nevada on June 29, 2007 under the name Legend Mining Inc. During the period from July 1, 2007 (inception) to June 30, 2011, the Company commenced operations by issuing shares and acquiring a mineral property located in the Province of Saskatchewan, Canada. The Company was unable to keep the mineral claim in good standing due to lack of funding, and accordingly its interest in it has expired. On October 10, 2011, the Company completed a merger with its wholly-owned subsidiary, Stevia First Corp., whereby it changed its name to “Stevia First Corp.” In connection with a related change in management, the addition of key personnel, and the lease of property for laboratory and office space in California, the Company is now pursuing its new business as an agricultural biotechnology company engaged in the cultivation and harvest of stevia leaf and the development of stevia products. The Company has not produced any revenues and is considered a development stage company. The Company's fiscal year end is March 31.

	Going Concern

	These financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception resulting in an accumulated deficit of $5,855,022 as at September 30, 2013, and further losses are anticipated in the development of its business. The Company also had a stockholders’ deficit of $1,459,714 at September 30, 2013. These factors raise substantial doubt about the Company's ability to continue as a going concern. As a result, the Company’s independent registered public accounting firm, in their report on the Company’s March 31, 2013 financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

	The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management believes that it has sufficient cash to fund operations for at least six months; however, management does not currently believe its existing cash resources are sufficient to meet its anticipated needs during the next twelve months. As reflected in the financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, and has limited working capital. The Company expects to incur substantial expenditures for the foreseeable future for the research, development and commercialization of its potential products. In addition, the Company will require additional financing in order to seek to license or acquire new assets, research and develop any potential patents and the related compounds, and obtain any further intellectual property that the Company may seek to acquire. The Company does not have sufficient cash and cash equivalents to support its current operating plan. The Company will be required to raise additional capital, obtain alternative means of financial support, or both, in order to continue to fund operations. Therefore, there exists substantial doubt about the Company’s ability to continue as a going concern. Additional financing may not be available to the Company when needed or, if available, it may not be obtained on commercially reasonable terms. If the Company is not able to obtain the necessary additional financing on a timely basis, the Company will be forced to delay or scale down some or all of its development activities or perhaps even cease the operation of its business. Historically, the Company has funded its operations primarily through equity and debt financings and it expects that it will continue to fund its operations through equity and debt financing. If the Company raises additional financing by issuing equity securities, its existing stockholders’ ownership will be diluted. Obtaining commercial loans, assuming those loans would be available, will increase the Company’s liabilities and future cash commitments. The Company also expects to pursue non-dilutive financing sources. However, obtaining such financing would require significant efforts by the Company’s management team, and such financing may not be available, and if available, could take a long period of time to obtain.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates and Assumptions

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumption by management include, among others, the fair value of shares issued for services, fair value of warrants issued in conjunction with convertible debentures, and assumptions used in the valuation of conversion features and derivative liabilities.

Financial Assets and Liabilities Measured at Fair Value

The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the condensed balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by the Financial Accounting Standards Board (“FASB”) defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets:

Level 1

Quoted prices in active markets for identical assets or liabilities.

Level 2

Inputs, other than the quoted prices in active markets, that is observable either directly or indirectly.

Level 3

Unobservable inputs based on the Company’s assumptions.

The following table presents certain investments and liabilities of the Company’s financial assets measured and recorded at fair value on the Company’s condensed balance sheets on a recurring basis and their level within the fair value hierarchy as of September 30, 2013 and March 31, 2013:

30-Sep-13

Level 1

Level 2

Level 3

Total

Fair value of Derivative Liability

1,369,517

31-Mar-13

Level 1

Level 2

Level 3

Total

Fair value of Derivative Liability

398,603

The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

Derivative Financial Instruments

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the September 30, 2013 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

Income Taxes

The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date.

Stock-Based Compensation

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.

Basic and Diluted Loss Per Share

The Company computes loss per share in accordance with ASC 260, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive.

As of September 30, 2013, the Company has no potential dilutive instruments and accordingly basic loss and diluted loss per share are the same. Options to acquire 3,975,000 shares of common stock, warrants to acquire 12,403,601 shares of common stock and 999,328 common shares potentially issuable under convertible note agreements have been excluded from the calculation at September 30, 2013 as the effect would have been anti-dilutive.

Recent Accounting Pronouncements

In March 2013, the FASB issued Accounting Standards Update (“ASU”) 2013-05 (Topic 830), “Foreign Currency Matters” (“ASU 2013-05”). ASU 2013-05 resolves the diversity in practice about whether Subtopic 810-10, Consolidation—Overall, or Subtopic 830-30, ASU 2013-05 applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, the amendments in this update resolve the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. ASU 2013-02 became effective for the company prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material effect on the Company’s financial statements.

The FASB has issued ASU No. 2013-04, Liabilities (Topic 405), “Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date” (“ASU 2013-04”). ASU 2013-04 provides guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this ASU is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s financial statements.

In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740) “Presentation of Unrecognized Tax Benefit When a Net Operating Loss Carryforward, A Similar Tax Loss, or a Tax Credit Carryforward Exists (A Consensus the FASB Emerging Issues Task Force)” (“ASU 2013-11”). ASU 2013-11 provides guidance on financial statement presentation of unrecognized tax benefit when a net operating loss carrforward, a similar tax loss, or a tax credit carryforward exists. The FASB’s objective in issuing this ASU is to eliminate diversity in practice resulting from a lack of guidance on this topic in current U.S. GAAP. This ASU applies to all entities with unrecognized tax benefits that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date. This update is effective for public entities for fiscal years beginning after December 15, 2013 and interim periods within those years. The Company does not expect the adoption of this standard to have a material impact on the Company’s financial statements.

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the Securities and Exchange Commission (“SEC”) did not or are not believed by management to have a material impact on the Company's present or future financial statements.

CONVERTIBLE_NOTES_PAYABLE

CONVERTIBLE NOTES PAYABLE	6 Months Ended
	Sep. 30, 2013
Convertible Note Payable [Abstract]	'
CONVERTIBLE NOTES PAYABLE	'
	3. CONVERTIBLE NOTES PAYABLE

	Convertible notes payable consist of the following as of September 30, 2013 and March 31, 2013:

		September 30,		March 31,
		2013		2013
	Subordinated unsecured convertible notes payable, interest at 6% per	$	625,000	$	625,000
	annum payable semi-annually
	Convertible notes payable		137,500		330,000
	Total convertible notes		762,500		955,000

	Less: note discount		-158,254		-374,592
	Convertible notes payable, net of note discount	$	604,246	$	580,408

	(a) On February 7, 2012, the Company entered into a Subscription Agreement (the “Subscription Agreement”) with one investor in a private placement, pursuant to which such investor irrevocably agreed to purchase $1,250,000 in common stock and convertible debentures from the Company over a twelve month period beginning on March 1, 2012. Under the Subscription Agreement, the investor agreed to purchase an aggregate of (i) 625,000 shares of common stock and (ii) convertible debentures with an aggregate principal amount of $625,000 convertible into a total of 693,774 shares of our common stock at prices ranging from $0.65 to $1.25, in five tranches, for proceeds to us of $250,000 per tranche. The conversion price of the common stock underlying each of the convertible debentures is subject to adjustment upon a reclassification or other change in the Company’s outstanding common stock and certain distributions to all holders of the Company’s common stock. The entire principal balance of each debenture is due and payable three years following its date of issuance unless earlier redeemed by the Company in accordance with its terms. Each of these convertible debentures bears interest at the rate of 6.0 % per annum, payable semi-annually in arrears on June 30 and December 31 of each year. During the three months ended June 30, 2013, the aggregate accrued interest due on these convertible debentures of $18,750 was converted into 20,816 shares of the Company’s common stock based on the conversion rates of the five tranches of these convertible debentures ranging from $0.65 to $1.25 per share. As of September 30, 2013, all $625,000 of these convertible debentures were outstanding. If the outstanding principal on all of the convertible debentures issued pursuant to the Subscription Agreement were converted into common shares, as of September 30, 2013, the holders thereof would receive 693,773 shares of common stock.

	During the year ended March 31, 2012, the Company had issued convertible notes under the Subscription Agreement where the market price of our common shares was in excess of the conversion price, creating a beneficial conversion feature of $177,404 upon issuance, representing the amount by which the value of the shares into which the notes are convertible exceeded the aggregate conversion price on the date of issuance. The beneficial conversion feature was recorded as a discount to the notes payable and is being amortized over the life of the notes, the balance of which was $113,341 at March 31, 2013. During the six months ended September 30, 2013, the Company recognized interest expense of $29,568 relating to the amortization of this discount, resulting in an unamortized balance of $83,773 as of September 30, 2013.

	(b) On October 29, 2012, we entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with two investors providing for the issuance and sale of an aggregate of $500,000 in convertible debentures and warrants to purchase 1,000,000 shares of our common stock, for proceeds to us of $500,000. The financing closed on November 1, 2012. After deducting for fees and expenses, the aggregate net proceeds from the sale of the debentures and warrants was $445,000. During the year ended March 31, 2013, $170,000 of these debentures were converted into shares of the Company’s common stock leaving a balance due on these debentures at March 31, 2013 of $330,000. During the six months ended September 30, 2013, $192,500 of the debentures were converted into 427,778 shares of common stock, and the remaining balance due on these debentures at September 30, 2013 was $137,500 .

	The debentures are non-interest bearing and mature on November 1, 2014. The debentures are convertible at the purchaser’s option into shares of the Company’s common stock (the “Conversion Shares”) at an initial conversion price of $0.50 per share, subject to adjustment for stock dividends and splits, subsequent rights offerings and pro rata distributions to the Company’s common stockholders. Upon the earlier of the effectiveness of a registration statement registering the Conversion Shares and Warrant Shares or the date the Conversion Shares and Warrant Shares may be sold pursuant to Rule 144 under the Securities Act of 1933 (the “Securities Act”) without volume or manner-of-sale restrictions (such earlier date, the “Trigger Date”), the conversion price of the debentures shall be reduced to the lesser of (i) the then conversion price or (ii) 90% of the average of the volume weighted average price of the Company’s common stock for the five trading days immediately prior to the Trigger Date, provided that the conversion price shall not be reduced to less than $0.35 per share (such adjusted conversion price, the “Reset Conversion Price”). Upon the effectiveness of the registration statement registering the shares issuable upon the conversion and exercise of the debentures and warrants on March 6, 2013, the conversion price of the debentures was reduced to $0.45. As such, if the $137,500 outstanding principal on these debentures were converted into common stock as of September 30, 2013, the holders thereof would receive 305,555 shares of common stock based on the reset conversion price per share of $0.45. We may force conversion of the debentures into common stock if, at any time, the volume weighted average price of our common stock for each of any five consecutive trading days exceeds 120% of the Reset Conversion Price. The Company may force conversion of the debentures into Conversion Shares if, at any time following the Trigger Date, the volume weighted average price of the Company’s common stock for each of any five consecutive trading days exceeds 120% of the Reset Conversion Price. The debentures provide for certain restrictive covenants and events of default which, if any of them occurs, would permit or require the principal amount of the debentures to become or to be declared due and payable. As the initial conversion price was greater than the market value of our common stock as of the date of issuance the Company did not recognize any beneficial conversion feature upon issuance. The Company considered the current FASB guidance of “Determining Whether an Instrument Indexed to an Entity’s Own Stock” in its accounting for the debenture as to the potential change to the conversion price which is based upon a future "trigger event" that has not taken place or may not take place, and determined that the conversion price of the notes are fixed until the contingency is triggered. The Company considers the conversion feature to be indexed to the Company’s own stock, and as such, no further accounting is appropriate at this time. The Warrants related to the note issuance are described below and resulted in a freestanding derivative valued at $523,458 upon issuance.

	Each of the purchasers was issued a warrant to purchase up to a number of shares of the Company’s common stock equal to 100 % of the Conversion Shares initially issuable to such purchaser pursuant to the Securities Purchase Agreement, totaling up to 1,000,000 shares of common stock (the “Warrant Shares”). The warrants had an initial exercise price of $0.70 per share, are exercisable immediately upon issuance and have a term of exercise equal to five years. The Company also issued warrants to purchase up to 80,000 shares of the Company’s common stock to its placement agent related to the financing that had an initial exercise price of $0.625 per share. On March 6, 2013, the exercise price of all the warrants was reduced to $0.50. On June 28, 2013, the exercise price of all of the warrants issued in the October 2012 financing was further reduced to $0.34.

	Each of the warrants includes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants issued with the convertible debentures, provided that the exercise price shall not be reduced to less than $0.20 per share. The Company considered the current FASB guidance of “Determining Whether an Instrument Indexed to an Entity’s Own Stock” and determined that the exercise price of the warrants is not a fixed amount because it is subject to fluctuation based on the occurrence of future offerings or events. As a result, the Company determined that the warrants are not considered indexed to the Company’s own stock and characterized the initial fair value of these warrants as a derivative liability upon issuance. The Company determined the aggregate initial fair value of the warrants issued to investors and placement agent to be $523,458 upon issuance. These amounts were determined by management using a using a probability weighted average Black-Scholes Merton option pricing model.

	The total costs of the loan were $578,458 which includes placement fees and expenses of $55,000 and the fair value of the warrant derivative of $523,458. To account for the these costs, the Company recorded a valuation discount of $500,000 upon issuance, and the incremental cost of $78,458 over the face amount of the note was recorded as a financing cost during the year ended March 31, 2013. The Company is amortizing the valuation discount to interest expense over the life of the notes. During the six months ended September 30, 2013, the Company recognized interest expense of $186,770 relating to the amortization of this discount, resulting in an unamortized balance of $74,481 as of September 30, 2013.

DERIVATIVE_LIABILITY

DERIVATIVE LIABILITY	6 Months Ended
DERIVATIVE LIABILITY	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
DERIVATIVE LIABILITY	'
	4. DERIVATIVE LIABILITY

	In June 2008, the FASB issued authoritative guidance on determining whether an instrument (or embedded feature) is indexed to an entity’s own stock. Under the authoritative guidance, effective January 1, 2009, instruments which do not have fixed settlement provisions are deemed to be derivative instruments. The warrants issued to investors and placement agents in relation to the securities purchase agreements described in Notes 3 and 5 do not have fixed settlement provisions because their exercise prices will be lowered if the Company issues securities at lower prices in the future. The Company was required to include the reset provisions in order to protect the holders of the convertible notes from the potential dilution associated with future financings. In accordance with the FASB authoritative guidance, the warrants issued in conjunction with the convertible notes have been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations.

	At March 31, 2013, and as of September 30, 2013, the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions:

	Warrants:

		September 30,			At Date of			March 31,
		2013			Issuance			2013
	Exercise Price	$	0.34-0.60		$	0.40 - $0.60		$	0.5
	Stock Price	$	0.35		$	0.35		$	0.45

	Risk-free interest rate		.02-1.295	%		2.52	%		0.25	%
	Expected volatility		78.7	%		78.7	%		123.68	%
	Expected life (in years)		0.25-4.75 years			0.50 - 5.0 years			4.5 years
	Expected dividend yield		0			0			0
	Fair Value:	$	1,369,517		$	1,249,025		$	398,603

	The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration date of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.

	At March 31, 2013, the fair value of the derivative liability was $398,603. During the six months ended September 30, 2013, we recognized an additional derivative liability of $1,249,025 related to the issuance of warrants on June 28, 2013 described in Note 5. As of September 30, 2013 the derivative liability of all outstanding warrants was $1,369,517. For the six months ended September 30, 2013, the Company recorded a change in fair value of the derivative liability of $278,111.

EQUITY

EQUITY	6 Months Ended
EQUITY	Sep. 30, 2013
E Q U I T Y [Abstract]	'
EQUITY	'
	5. EQUITY

	Equity financing

	On June 25, 2013, the Company entered into a Securities Purchase Agreement with three (3) investors for sale of an aggregate of 3,676,472 shares of the Company's common stock and warrants to purchase 11,029,416 shares of the Company’s common stock for total gross proceeds of $1,250,000, or a sales price of $0.34 per share. The offering closed on June 28, 2013. The Company incurred $116,750 of direct costs in connection with the financing, resulting in net cash proceeds to the Company of $1,133,250. The purchasers who entered into the Securities Purchase Agreement were also issued warrants to purchase up to 11,029,416 shares of the Company’s common stock. The warrants were issued in three groups of 3,676,472 each and have initial exercise prices of $0.40, $0.50 and $0.60 per share, respectively, are exercisable immediately upon issuance and have a term of exercise equal to five years. The Company also issued warrants to purchase up to 294,185 shares of the Company’s commons stock to its placement agent related to the financing. The placement agent warrants have an exercise price of $0.425 per share and a term of five years and are exercisable immediately.

	Each of the warrants includes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants issued with the convertible debentures, provided that the exercise price shall not be reduced to less than $0.20 per share. The Company considered the current FASB guidance of “Determining Whether an Instrument Indexed to an Entity’s Own Stock” and determined that exercise price of the warrants are not a fixed amount because they are subject to fluctuation based on the occurrence of future offerings or events. As a result, the Company determined that the warrants are not considered indexed to the Company’s own stock and characterized the initial fair value of these warrants as derivative liabilities upon issuance. The Company determined the aggregate initial fair value of the warrants issued to investors and the placement agent in the financing to be $1,249,025 at issuance based upon a weighted average black-scholes option pricing model. For financial statement purposes, the amount of the derivative liability created from the issuance of the warrants of $1,249,025 has been offset to the net cash proceeds received of $1,133,250, resulting in a net reduction of additional paid in capital of $115,775 resulting from the sale of the units.

	Common stock issued to employees

	In July and August 2012, the Company issued an aggregate of 700,000 shares of its common stock to employees and a director of the Company vesting over a period ranging from 16 months to 60 months from the date of grant under the Company's 2012 Stock Incentive Plan. These shares of common stock issued to employees and a director were valued based upon the market price of the Company’s common stock at the dates of grant for an aggregate fair value of $189,000. As the shares were issued, but not yet vested, the aggregate fair value of these shares was accounted for as a contra-equity account that is being amortized over the vesting term of the common stock award. During the six months ended September 30, 2013, the Company amortized $24,545 of the fair value of the common stock as services were provided and recognized as stock compensation in the Company’ s statement of operations, and $132,955 remained unamortized as of the period then ended.

	In July 2013, the Company issued 100,000 shares of its common stock to an employee of the Company vesting over a period of 31 months from the date of grant under the Company's 2012 Stock Incentive Plan. These shares of common stock issued to employee were valued based upon the market price of the Company’s common stock at the date of grant for an aggregate fair value of $36,000. As the shares were issued, but not yet vested, the aggregate fair value of these shares was accounted for as a contra-equity account that is being amortized over the vesting term of the common stock award. During the six months ended September 30, 2013, the Company amortized $3,484 of the fair value of the common stock as services were provided and recognized as stock compensation in the Company’ s statement of operations, and $32,516 remained unamortized as of the period then ended.

STOCK_OPTIONS

STOCK OPTIONS	6 Months Ended
STOCK OPTIONS	Sep. 30, 2013
Stock Options [Abstract]	'
STOCK OPTIONS	'
	6. STOCK OPTIONS

	The Company has adopted a stock option and incentive plan (the “2012 Stock Incentive Plan”). Pursuant to the terms of the 2012 Stock Incentive Plan, the exercise price for all equity awards issued under the 2012 Stock Incentive Plan is based on the market price per share of the Company’s common stock on the date of grant of the applicable award.

	A summary of the Company’s stock option activity for the period ended September 30, 2013 is presented below:

		Shares		Weighted
				Average
				Exercise
				Price
	Balance at March 31, 2013		2,275,000	$	0.16
	Granted		3,300,000		0.39
	Exercised		-
	Cancelled		-100,000		0.42
	Balance outstanding at September 30, 2013		5,475,000	$	0.26
	Balance exercisable at September 30, 2013		3,850,000	$	0.28

	At September 30, 2013, options to purchase common shares were outstanding as follows:

		Number of		Weighted		Weighted
		options		Average		Average
				Exercise		Grant-date Stock
				Price		Price

	Options Outstanding, September 30, 2013		1,650,000	$	0.1	$	1
			100,000	$	0.27	$	0.27
			300,000	$	0.28	$	0.27
			1,500,000	$	0.32	$	0.32
			300,000	$	0.35	$	0.35
			1,500,000	$	0.4	$	0.4
			125,000	$	0.42	$	0.42

			5,475,000

	Exercisable, September 30, 2013		1,075,000	$	0.1	$	1
			25,000	$	0.27	$	0.27
			200,000	$	0.28	$	0.27
			1,000,000	$	0.32	$	0.32
			50,000	$	0.35	$	0.35
			1,500,000	$	0.4	$	0.4
			3,850,000

	During the six months ended September 30, 2013, the Company granted 1,800,000 options to consultants that expire ten years from date of grant and granted 1,500,000 options to consultants that expire three years from date of grant. Assumptions used in valuing stock options granted during the six months ended September 30, 2013 are as follows: (i) volatility rate of 78.7%, (ii) discount rate of between 0.25% and 0.63%, (iii) zero expected dividend yield, and (iv) expected life of 3 or 10 years for those options granted to consultants based upon the contractual term of the options and an expected life of approximately 5 years for those granted to employees. For employees the expected life is the average of the term of the option and the vesting period. The value of the options at grant date was $419,550, all of which was amortized as compensation cost during the six months ended September 30, 2013, as all of these options were vested as of September 30, 2013.

	During the six months ended September 30, 2013 and 2012, we expensed total stock-based compensation related to vesting stock options of $665,873 and $595,713, respectively, and the remaining unamortized cost of the outstanding stock-based awards at September 30, 2013 was $503,553. This cost will be amortized on a straight line basis over a weighted average remaining vesting period of 2 years and will be adjusted for subsequent changes in estimated forfeitures. Future option grants will increase the amount of compensation expense that will be recorded.

	The intrinsic value of all outstanding stock options at September 30, 2013, was $489,500.

WARRANTS

WARRANTS	6 Months Ended
	Sep. 30, 2013
Warrants [Abstract]	'
WARRANTS	'
	7. WARRANTS

	At September 30, 2013, warrants to purchase common shares were outstanding as follows:

		Shares		Weighted
				Average
				Exercise
				Price
	Balance at March 31, 2013		1,080,000	$	0.5
	Granted		11,323,601		0.5
	Exercised		-
	Cancelled		-	$	-
	Balance outstanding at September 30, 2013		12,403,601	$	0.5
	Balance exercisable at September 30, 2013		12,403,601

	The purchasers who entered into the Securities Purchase Agreement on October 29, 2012 described in Note 3, were issued warrants to purchase up to 1,000,000 shares of the Company’s common stock. The warrants have an initial exercise price of $0.70 per share, are exercisable immediately upon issuance and have a term of exercise equal to five years. On March 6, 2013, the exercise price of the warrants was reduced to $0.50. We also issued warrants to purchase up to 80,000 shares of the Company’s commons stock to the placement agent in the offering. The placement agent warrants had an initial exercise price of $0.625 per share and a term of five years and are exercisable immediately. The exercise price of the placement agent warrants was reduced to $0.50 on March 6, 2013. On June 28, 2013, the exercise price of the placement agent warrants was further reduced to $0.34.

	The purchasers who entered into the Securities Purchase Agreement on June 25, 2013 described in Note 5 were issued warrants to purchase up to 11,029,416 shares of the Company’s common stock. The warrants were issued in three series of 3,676,472 each and have initial exercise prices of $0.40, $0.50 and $0.60 per share, respectively, are exercisable immediately upon issuance and have a term of exercise equal to five years, six months and nine months, respectively. The Company also issued warrants to purchase up to 294,185 shares of the Company’s common stock to its placement agent in the financing. The placement agent warrants have an exercise price of $0.425 per share and a term of five years and are exercisable immediately.

	Each of the warrants includes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants issued with the convertible debentures, as well as for stock dividends and splits, subsequent rights offerings and pro rata distributions to our common stockholders, provided that the exercise price shall not be reduced to less than $0.20 per share. The Company considered the current FASB guidance of “Determining Whether an Instrument Indexed to an Entity’s Own Stock” and determined that exercise price of the warrants are not a fixed amount because they are subject to fluctuation based on the occurrence of future offerings or events. As a result, the Company determined that the warrants are not considered indexed to the Company’s own stock and characterizes the fair value of these warrants as derivative liabilities (See Note 4).

INCOME_TAXES

INCOME TAXES	6 Months Ended
INCOME TAXES	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	8. INCOME TAXES

	The Company has no tax provision for any period presented due to our history of operating losses. As of September 30, 2013, the Company had net operating loss carry forwards of approximately $5,073,342 that may be available to reduce future years' taxable income through 2029. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as management has determined that their realization is not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards.

RELATED_PARTY_TRANSACTIONS_AND

RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS	6 Months Ended
RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS	Sep. 30, 2013
Related Party Transactions and Lease Obligations Disclosure [Abstract]	'
RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS	'
	9. RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS

	Advance payment of related party lease

	On April 23, 2012, the Company entered into a lease agreement (the “Sutter Lease”) with Sutter Buttes LLC (“Sutter Buttes”), pursuant to which the Company has agreed to lease from Sutter Buttes approximately 1,000 acres of land in Sutter County, California on which the Company may either cultivate and harvest the stevia plant or locate stevia processing facilities. The Sutter Lease begins on May 1, 2012 and expires on May 1, 2014 and the Company has paid the aggregate amount of all rent payments thereunder, totaling $250,000. Sutter Buttes, the landlord under the Sutter Lease, is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains.

	The amount of all rent payments under the Sutter Lease of $250,000 was accounted for by the Company as an asset, Advance payment of related party lease, and is being amortized over the term of the lease of 24 months. During the six months ended September 30, 2013, the Company recognized rent expense of $62,500 related to the Sutter Lease. As of September 30, 2013, the unamortized advance payment of the related party lease was $72,917.

	Other related party lease obligations

	Effective as of September 1, 2011, the Company entered into an unsecured lease agreement with World Ranches LLC (“One World Ranches”), which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains, for office and laboratory space located at 5225 Carlson Rd., Yuba City, CA 95993 for a term of five years expiring on September 1, 2016 at a rate of $1,000 per month. Effective as of January 1, 2012, the Company modified the lease agreement to provide for additional office and laboratory space for an additional $500 per month, for a total rental payment of $1,500 per month.

	On April 23, 2012, the Company entered into a further lease agreement with One World Ranches, pursuant to which the Company has agreed to lease from One World Ranches certain office and laboratory space located at 5225 Carlson Road, Yuba City, California , which supersedes and replaces the prior lease (such current lease agreement, the “Carlson Lease”) . The Carlson Lease began on May 1, 2012 and expires on May 1, 2017, and the Company’s rent payments thereunder are $2,300 per month. The Company has paid $1,500 as a refundable security deposit under the Carlson Lease.

	On August 18, 2012, the Company entered into a lease agreement (the “Sacramento Lease”) with Sacramento Valley Real Estate, which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains, pursuant to which the Company leases an apartment located at 33-800 Clark Avenue, Yuba City, California. This Company uses this apartment as an alternative to renting hotel rooms for management use since several of our managers are not resident in Yuba City. The month to month lease began on August 20, 2012 and the Company’s rent payment is $1,000 per month. On August 22, 2012, the Company paid $1,000 as a refundable security deposit under the Sacramento lease.

	Aggregate payments under the above leases for the six months ended September 30, 2013 and 2012 were $82,300 and $66,450, respectively.

COMMITMENTS

COMMITMENTS	6 Months Ended
COMMITMENTS	Sep. 30, 2013
Commitments And Contingencies Disclosure [Abstract]	'
COMMITMENTS	'
	10. COMMITMENTS

	We have exclusive and worldwide rights to patents and patent applications obtained through a license agreement with Vineland Research and Innovations Centre, Inc. entered into in August 2012 and amended in October 2013 (the “Vineland License”). The patent family includes an issued U.S. patent, an issued European Union patent, and an issued Canadian patent. The patents and patent applications relate to microbial production of steviol and steviol glycosides. The Vineland License has an initial term of 10 years and may be renewed by us for additional two-year terms until all licensed patents have expired. Pursuant to the Vineland License, we agreed to total cash fees due and payable within the first year of $50,000 , of which $37,500 has been paid and recorded as expenses, with the remaining balance of $12,500 due on the one (1) year anniversary date of the Vineland License. In addition to these cash fees, we will owe royalties of 0.5 % of the sale price of products developed using the intellectual property, and in the third year and all subsequent years of the Vineland License the Company will owe a minimum annual royalty of $10,000. In the amendment to the Vineland License, Vineland agreed to license to us an additional patent application and to pay up to $50,000 in patent prosecution cost related to the new patent application.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	11. SUBSEQUENT EVENTS

	The Company granted options to purchase 100,000 shares of the Company’s common stock in October 2013 under the 2012 Stock Incentive Plan to one consultant. These options vest over three years.

	In October 2013, convertible notes payable with a principal amount of $50,000 were converted into 111,112 shares of the Company’s common stock and warrants to purchase 500,000 shares of the Company’s common stock were exercised in exchange to $170,000.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Sep. 30, 2013

Accounting Policies [Abstract]

Use of Estimates and Assumptions

Financial Assets and Liabilities Measured at Fair Value

Level 1

Quoted prices in active markets for identical assets or liabilities.

Level 2

Inputs, other than the quoted prices in active markets, that is observable either directly or indirectly.

Level 3

Unobservable inputs based on the Company’s assumptions.

30-Sep-13

Level 1

Level 2

Level 3

Total

Fair value of Derivative Liability

1,369,517

31-Mar-13

Level 1

Level 2

Level 3

Total

Fair value of Derivative Liability

398,603

Derivative Financial Instruments

Income Taxes

Stock-Based Compensation

Basic and Diluted Loss Per Share

Recent Accounting Pronouncements

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	Sep. 30, 2013
Accounting Policies [Abstract]	'
Investments and Liabilities of the Companys Financial Assets	'
	The following table presents certain investments and liabilities of the Company’s financial assets measured and recorded at fair value on the Company’s condensed balance sheets on a recurring basis and their level within the fair value hierarchy as of September 30, 2013 and March 31, 2013:

	30-Sep-13

		Level 1		Level 2		Level 3		Total
	Fair value of Derivative Liability	$	-	$	1,369,517	$	-	$	1,369,517

	31-Mar-13

		Level 1		Level 2		Level 3		Total
	Fair value of Derivative Liability	$	-	$	398,603	$	-	$	398,603

CONVERTIBLE_NOTES_PAYABLE_Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	6 Months Ended
	Sep. 30, 2013
Convertible Note Payable [Abstract]	'
Convertible Notes Payable	'
	Convertible notes payable consist of the following as of September 30, 2013 and March 31, 2013:

		September 30,		March 31,
		2013		2013
	Subordinated unsecured convertible notes payable, interest at 6% per	$	625,000	$	625,000
	annum payable semi-annually
	Convertible notes payable		137,500		330,000
	Total convertible notes		762,500		955,000

	Less: note discount		-158,254		-374,592
	Convertible notes payable, net of note discount	$	604,246	$	580,408

	(a) On February 7, 2012, the Company entered into a Subscription Agreement (the “Subscription Agreement”) with one investor in a private placement, pursuant to which such investor irrevocably agreed to purchase $1,250,000 in common stock and convertible debentures from the Company over a twelve month period beginning on March 1, 2012. Under the Subscription Agreement, the investor agreed to purchase an aggregate of (i) 625,000 shares of common stock and (ii) convertible debentures with an aggregate principal amount of $625,000 convertible into a total of 693,774 shares of our common stock at prices ranging from $0.65 to $1.25, in five tranches, for proceeds to us of $250,000 per tranche. The conversion price of the common stock underlying each of the convertible debentures is subject to adjustment upon a reclassification or other change in the Company’s outstanding common stock and certain distributions to all holders of the Company’s common stock. The entire principal balance of each debenture is due and payable three years following its date of issuance unless earlier redeemed by the Company in accordance with its terms. Each of these convertible debentures bears interest at the rate of 6.0 % per annum, payable semi-annually in arrears on June 30 and December 31 of each year. During the three months ended June 30, 2013, the aggregate accrued interest due on these convertible debentures of $18,750 was converted into 20,816 shares of the Company’s common stock based on the conversion rates of the five tranches of these convertible debentures ranging from $0.65 to $1.25 per share. As of September 30, 2013, all $625,000 of these convertible debentures were outstanding. If the outstanding principal on all of the convertible debentures issued pursuant to the Subscription Agreement were converted into common shares, as of September 30, 2013, the holders thereof would receive 693,773 shares of common stock.

	During the year ended March 31, 2012, the Company had issued convertible notes under the Subscription Agreement where the market price of our common shares was in excess of the conversion price, creating a beneficial conversion feature of $177,404 upon issuance, representing the amount by which the value of the shares into which the notes are convertible exceeded the aggregate conversion price on the date of issuance. The beneficial conversion feature was recorded as a discount to the notes payable and is being amortized over the life of the notes, the balance of which was $113,341 at March 31, 2013. During the six months ended September 30, 2013, the Company recognized interest expense of $29,568 relating to the amortization of this discount, resulting in an unamortized balance of $83,773 as of September 30, 2013.

	(b) On October 29, 2012, we entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with two investors providing for the issuance and sale of an aggregate of $500,000 in convertible debentures and warrants to purchase 1,000,000 shares of our common stock, for proceeds to us of $500,000. The financing closed on November 1, 2012. After deducting for fees and expenses, the aggregate net proceeds from the sale of the debentures and warrants was $445,000. During the year ended March 31, 2013, $170,000 of these debentures were converted into shares of the Company’s common stock leaving a balance due on these debentures at March 31, 2013 of $330,000. During the six months ended September 30, 2013, $192,500 of the debentures were converted into 427,778 shares of common stock, and the remaining balance due on these debentures at September 30, 2013 was $137,500 .

DERIVATIVE_LIABILITY_Tables

DERIVATIVE LIABILITY (Tables)	6 Months Ended
DERIVATIVE LIABILITY (Tables)	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Warrants	'
	At March 31, 2013, and as of September 30, 2013, the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions:

	Warrants:

		September 30,			At Date of			March 31,
		2013			Issuance			2013
	Exercise Price	$	0.34-0.60		$	0.40 - $0.60		$	0.5
	Stock Price	$	0.35		$	0.35		$	0.45

	Risk-free interest rate		.02-1.295	%		2.52	%		0.25	%
	Expected volatility		78.7	%		78.7	%		123.68	%
	Expected life (in years)		0.25-4.75 years			0.50 - 5.0 years			4.5 years
	Expected dividend yield		0			0			0
	Fair Value:	$	1,369,517		$	1,249,025		$	398,603

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	6 Months Ended
STOCK OPTIONS (Tables)	Sep. 30, 2013
Stock Options [Abstract]	'
Options to Purchase Common Shares	'
	A summary of the Company’s stock option activity for the period ended September 30, 2013 is presented below:

		Shares		Weighted
				Average
				Exercise
				Price
	Balance at March 31, 2013		2,275,000	$	0.16
	Granted		3,300,000		0.39
	Exercised		-
	Cancelled		-100,000		0.42
	Balance outstanding at September 30, 2013		5,475,000	$	0.26
	Balance exercisable at September 30, 2013		3,850,000	$	0.28

Stock Option Activity	'
	At September 30, 2013, options to purchase common shares were outstanding as follows:

		Number of		Weighted		Weighted
		options		Average		Average
				Exercise		Grant-date Stock
				Price		Price

	Options Outstanding, September 30, 2013		1,650,000	$	0.1	$	1
			100,000	$	0.27	$	0.27
			300,000	$	0.28	$	0.27
			1,500,000	$	0.32	$	0.32
			300,000	$	0.35	$	0.35
			1,500,000	$	0.4	$	0.4
			125,000	$	0.42	$	0.42

			5,475,000

	Exercisable, September 30, 2013		1,075,000	$	0.1	$	1
			25,000	$	0.27	$	0.27
			200,000	$	0.28	$	0.27
			1,000,000	$	0.32	$	0.32
			50,000	$	0.35	$	0.35
			1,500,000	$	0.4	$	0.4
			3,850,000

WARRANTS_Tables

WARRANTS (Tables)	6 Months Ended
WARRANTS (Tables)	Sep. 30, 2013
Warrants [Abstract]	'
Warrants	'
	At September 30, 2013, warrants to purchase common shares were outstanding as follows:

		Shares		Weighted
				Average
				Exercise
				Price
	Balance at March 31, 2013		1,080,000	$	0.5
	Granted		11,323,601		0.5
	Exercised		-
	Cancelled		-	$	-
	Balance outstanding at September 30, 2013		12,403,601	$	0.5
	Balance exercisable at September 30, 2013		12,403,601

BUSINESS_AND_BASIS_OF_OPERATIO1

BUSINESS AND BASIS OF OPERATIONS (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Nature And Continuance Of Operation [Line Items]	'	'
Accumulated deficit	$5,855,022	'
Stockholders' Equity	$1,459,714	$568,106

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Fair value of Derivative Liability (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Fair value of Derivative Liability	$1,369,517	$398,603
Fair Value, Inputs, Level 1 [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Fair value of Derivative Liability	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Fair value of Derivative Liability	1,369,517	398,603
Fair Value, Inputs, Level 3 [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Fair value of Derivative Liability	$0	$0

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'
Stock Options To Purchase	3,975,000
Common Shares Issuable Under Convertible Note	999,328
Warrant [Member]	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,403,601

CONVERTIBLE_NOTES_PAYABLE_Sche

CONVERTIBLE NOTES PAYABLE: Schedule of convertible notes payable (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
Extinguishment of Debt [Line Items]	'	'
Total convertible notes	$762,500	$955,000
Less: note discount	-158,254	-374,592
Convertible notes payable, net of note discount	604,246	580,408
Subordinated Unsecured Convertible Notes Payable Interest At Six Percent Per Annum Payable Semi Annually [Member]	'	'
Extinguishment of Debt [Line Items]	'	'
Total convertible notes	625,000	625,000
Convertible Notes Payable [Member]	'	'
Extinguishment of Debt [Line Items]	'	'
Total convertible notes	$137,500	$330,000

CONVERTIBLE_NOTES_PAYABLE_Deta

CONVERTIBLE NOTES PAYABLE (Details) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

75 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

3 Months Ended

Mar. 06, 2013

Oct. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Mar. 31, 2013

Mar. 31, 2012

Sep. 30, 2013

Oct. 29, 2012

Feb. 07, 2012

Oct. 31, 2012

Sep. 30, 2013

Mar. 06, 2013

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Mar. 31, 2012

Jun. 30, 2013

Sep. 30, 2013

Feb. 07, 2012

Jun. 30, 2013

Feb. 07, 2012

Jun. 30, 2013

Feb. 07, 2012

Placement Agent Agreement [Member]

Debentures [Member]

Warrant [Member]

Subordinated Unsecured Convertible Notes Payable Interest At Six Percent Per Annum Payable Quarterly [Member]

Subordinated Unsecured Convertible Notes Payable Interest At Six Percent Per Annum Payable Semi Annually [Member]

Convertible Debt [Member]

Minimum [Member]

Maximum [Member]

Per Tranche [Member]

Dawson [Member]

Subordinated Unsecured Convertible Notes Payable Interest At Six Percent Per Annum Payable Semi Annually [Member]

Extinguishment of Debt [Line Items]

Stock and convertible debentures sold for cash

$1,250,000

Common stock share amount

625,000

Convertible debenture amount

625,000

250,000

Debenture pursuant to Subscription Agreement

693,774

Debenture conversion price

$0.65

$1.25

Debt Instrument, Interest Rate, Stated Percentage

6.00%

Receivable Common Shares

693,773

Debt Instrument, Unamortized Discount

158,254

374,592

113,341

158,254

74,481

Interest Expense, Debt

29,568

186,770

Convertible Notes Payable

762,500

955,000

762,500

625,000

Debt Instrument, Convertible, Conversion Price

$0.50

$0.45

$0.65

$1.25

Fair value of beneficial conversion feature of convertible notes

177,404

Proceeds From Issuance Of Common Stock

500,000

1,133,250

Conversion of notes payable and accrued interest to common stock

1,249,025

18,750

20,816

Financing cost

78,458

Loan Costs Total

578,458

Loan Placement Fees

55,000

Derivative, Fair Value, Net

523,458

Warrants To Purchase Of Common Stock

1,000,000

Free Standing Derivative Value

500,000

Proceeds from Issuance or Sale of Equity

445,000

1,133,250

425,000

1,783,250

Conversion Shares Issuable To Purchaser Percentage

100.00%

Warrants Exercise Price

$0.34

$0.70

Debt Instrument, Description

'the conversion price of the debentures shall be reduced to the lesser of (i) the then conversion price or (ii) 90% of the average of the volume weighted average price of the Companys common stock for the five trading days immediately prior to the Trigger Date, provided that the conversion price shall not be reduced to less than $0.35 per share (such adjusted conversion price, the Reset Conversion Price). Upon the effectiveness of the registration statement registering the shares issuable upon the conversion and exercise of the debentures and warrants on March 6, 2013, the conversion price of the debentures was reduced to $0.45. As such, if the $137,500 outstanding principal on these debentures were converted into common stock as of September 30, 2013, the holders thereof would receive 305,555 shares of common stock based on the reset conversion price per share of $0.45. We may force conversion of the debentures into common stock if, at any time, the volume weighted average price of our common stock for each of any five consecutive trading days exceeds 120% of the Reset Conversion Price. The Company may force conversion of the debentures into Conversion Shares if, at any time following the Trigger Date, the volume weighted average price of the Companys common stock for each of any five consecutive trading days exceeds 120% of the Reset Conversion Price. The debentures provide for certain restrictive covenants and events of default which, if any of them occurs, would permit or require the principal amount of the debentures to become or to be declared due and payable. As the initial conversion price was greater than the market value of our common stock as of the date of issuance the Company did not recognize any beneficial conversion feature upon issuance. The Company considered the current FASB guidance of Determining Whether an Instrument Indexed to an Entitys Own Stock in its accounting for the debenture as to the potential change to the conversion price which is based upon a future "trigger event" that has not taken place or may not take place, and determined that the conversion price of the notes are fixed until the contingency is triggered. The Company considers the conversion feature to be indexed to the Companys own stock, and as such, no further accounting is appropriate at this time. The Warrants related to the note issuance are described below and resulted in a freestanding derivative valued at $523,458 upon issuance.

Conversion of Stock, Amount Converted

192,500

Conversion of Stock, Shares Issued

427,778

Debenture Outstanding Amount

137,500

330,000

Warrants Granted In Period

1,000,000

11,323,601

80,000

294,185

80,000

Warrants Granted Period In Weighted Exercise Price

0.5

0.7

0.5

0.425

0.5

0.625

Minimum Warrants Exercise Price

$0.20

Debt Conversion, Original Debt, Amount

$137,500

$170,000

Average Percentage Of Volume Weighted Average Price

90.00%

Reset Conversion Price

$0.35

Debt Instrument, Convertible, Number of Equity Instruments

305,555

Maximum Percentage Of Volume Weighted Average Price

120.00%

DERIVATIVE_LIABILITY_weighted_

DERIVATIVE LIABILITY: weighted average pricing model (Details) (USD $)	6 Months Ended	12 Months Ended
	Sep. 30, 2013	Mar. 31, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Exercise Price	'	$0.50
Stock Price	$0.35	$0.45
Risk-free interest rate	'	0.25%
Expected volatility	78.70%	123.68%
Expected life (in years)	'	'4 years 6 months
Expected dividend yield	0.00%	0.00%
Fair value of Derivative Liability	$1,369,517	$398,603
At Date of Issuance [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Stock Price	'	$0.35
Risk-free interest rate	'	2.52%
Expected volatility	'	78.70%
Expected dividend yield	'	0.00%
Fair value of Derivative Liability	$1,249,025	$1,249,025
Maximum [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Exercise Price	$0.60	'
Risk-free interest rate	1.30%	'
Expected life (in years)	'4 years 9 months	'
Maximum [Member] \| At Date of Issuance [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Exercise Price	'	$0.60
Expected life (in years)	'	'5 years
Minimum [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Exercise Price	$0.34	'
Risk-free interest rate	0.02%	'
Expected life (in years)	'3 months	'
Minimum [Member] \| At Date of Issuance [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Exercise Price	'	$0.40
Expected life (in years)	'	'6 months

DERIVATIVE_LIABILITY_Details

DERIVATIVE LIABILITY (Details) (USD $)	3 Months Ended		6 Months Ended		75 Months Ended
DERIVATIVE LIABILITY (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Mar. 31, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'	'
Fair value of Derivative Liability	$1,369,517	'	$1,369,517	'	$1,369,517	$398,603
Change in fair value of derivative liability	-93,090	0	-278,111	0	-402,966	'
At Date of Issuance [Member]	'	'	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'	'
Fair value of Derivative Liability	$1,249,025	'	$1,249,025	'	$1,249,025	$1,249,025

EQUITY_Details

EQUITY (Details) (USD $)

0 Months Ended

1 Months Ended

6 Months Ended

75 Months Ended

6 Months Ended

Mar. 06, 2013

Oct. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Warrant

Common Stock [Member]

Warrant [Member]

Warrant One [Member]

Warrant Two [Member]

Warrant Three [Member]

Placement Agent Agreement [Member]

Unvested Issued Common Stock [Member]

Stock Incentive Plan 2012 [Member]

employees and a director [Member]

Subscription Agreement [Member]

Warrant

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Shares, Conversion of Convertible Securities

1,250,000

Warrants Granted In Period

1,000,000

11,323,601

294,185

Stock Issued During Period Shares Conversion Of Convertible Securities Per Share

$0.34

Payments of Financing Costs, Total

$116,750

Shares sold

500,000

1,133,250

Warrants Granted Period In Weighted Exercise Price

0.5

0.7

0.5

0.4

0.5

0.6

0.425

Stock Issued During Period, Shares, New Issues

700,000

Stock Issued During Period, Value, Share-based Compensation, Gross

24,545

Unvested Issued Common Stock

132,955

Conversion of notes payable and accrued interest to common stock

1,249,025

Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants

-115,775

3,676

Stock and Warrants Issued During Period, Share, Preferred Stock and Warrants

3,676,472

Number of Common Stock To Be Issued Upon Exercise of Warrants

11,029,416

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value

419,550

189,000

Minimum Warrants Exercise Price

$0.20

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

100,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'31 months

Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount

3,484

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total

32,516

Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

$36,000

STOCK_OPTIONS_Purchase_common_

STOCK OPTIONS: Purchase common shares (Details) (USD $)	6 Months Ended
STOCK OPTIONS: Purchase common shares (Details) (USD $)	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares, Balance	2,275,000
Shares, Granted	3,300,000
Shares, Exercised	0
Shares, Cancelled	-100,000
Shares, Balance	5,475,000
Shares, Ending exercisable	3,850,000
Weighted Average Exercise Price, Balance	$0.16
Weighted Average Exercise Price, Granted	$0.39
Weighted Average Exercise Price, Cancelled	$0.42
Weighted Average Exercise Price, Balance	$0.26
Weighted Average Exercise Price, exercisable	$0.28

STOCK_OPTIONS_Stock_option_act

STOCK OPTIONS: Stock option activity (Details) (USD $)

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Stock Options 1 [Member]

Stock Options 2 [Member]

Stock Options 3 [Member]

Stock Option 4 [Member]

Stock Option 5 [Member]

Stock Options 6 [Member]

Stock Options 7 [Member]

Vested 1 [Member]

Vested 2 [Member]

Vested 3 [Member]

Vested 4 [Member]

Vested 5 [Member]

Vested 6 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options Outstanding

5,475,000

2,275,000

1,650,000

100,000

300,000

1,500,000

300,000

1,500,000

125,000

Weighted Average Exercise Price, Options Outstanding

$0.26

$0.16

$0.10

$0.27

$0.28

$0.32

$0.35

$0.40

$0.42

$0.10

$0.27

$0.28

$0.32

$0.35

$0.40

Weighted Average Grant-Date Stock Price, Options Outstanding

$0.27

$0.32

$0.35

$0.40

$0.42

Options vested

1,075,000

25,000

200,000

1,000,000

50,000

1,500,000

Weighted Average Grant-Date Stock Price, Vested

$0.27

$0.32

$0.35

$0.40

Shares, Ending exercisable

3,850,000

STOCK_OPTIONS_Details

STOCK OPTIONS (Details) (USD $)	6 Months Ended
STOCK OPTIONS (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share based Compensation Arrangement By Share based Payment Award Grants Expected Term	'5 years	'
Total stock-based compensation expensed	$665,873	$595,713
Unamortized cost of outstanding stock-based awards	503,553	'
Weighted Average Remaining Vesting Period	'2 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	489,500	'
Volatility, Options Outstanding	78.70%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	'
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value	419,550	'
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions	0.25%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'3 years	'
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions	0.63%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'10 years	'
Consultants One [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	1,800,000	'
Consultants Two [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	1,500,000	'
Stock Incentive Plan 2012 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value	$189,000	'

WARRANTS_Warrants_to_purchase_

WARRANTS: Warrants to purchase common shares (Details) (USD $)	0 Months Ended	1 Months Ended	6 Months Ended
	Mar. 06, 2013	Oct. 31, 2012	Sep. 30, 2013
Class of Warrant or Right [Line Items]	'	'	'
Shares, Balance	'	'	1,080,000
Shares, Granted	'	1,000,000	11,323,601
Shares, Exercised	'	'	0
Shares, Cancelled	'	'	0
Shares, Balance	'	'	12,403,601
Shares, exercisable	'	'	12,403,601
Weighted Average Exercise Price, Balance	'	'	0.5
Weighted Average Exercise Price, Granted	0.5	0.7	0.5
Weighted Average Exercise Price, Cancelled	'	'	$0
Weighted Average Exercise Price Balance	'	'	0.5

WARRANTS_Details

WARRANTS (Details) (USD $)

0 Months Ended

1 Months Ended

6 Months Ended

75 Months Ended

6 Months Ended

9 Months Ended

6 Months Ended

9 Months Ended

6 Months Ended

9 Months Ended

1 Months Ended

6 Months Ended

0 Months Ended

6 Months Ended

12 Months Ended

Mar. 06, 2013

Oct. 31, 2012

Sep. 30, 2013

Oct. 31, 2012

Sep. 30, 2013

Mar. 06, 2013

Sep. 30, 2013

Mar. 31, 2013

Warrant

Warrant One [Member]

Warrant Two [Member]

Warrant Three [Member]

Placement Agent Agreement [Member]

Dawson [Member]

Class of Warrant or Right [Line Items]

Shares, Granted

1,000,000

11,323,601

3,676,472

80,000

294,185

80,000

Warrants Granted Period In Weighted Exercise Price

0.5

0.7

0.5

0.4

0.5

0.6

0.425

0.5

0.625

Warrants Exercise Price

$0.34

Number of Common Stock To Be Issued Upon Exercise of Warrants

11,029,416

Minimum Warrants Exercise Price

$0.20

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Sep. 30, 2013
Operating Loss Carryforwards [Line Items]	'
Net operating loss carry forwards	$5,073,342

RELATED_PARTY_TRANSACTIONS_AND1

RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS (Details) (USD $)

1 Months Ended

6 Months Ended

Sep. 30, 2011

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Aug. 20, 2012

Jan. 31, 2012

Sep. 01, 2011

Sep. 30, 2013

Apr. 23, 2012

Sep. 30, 2013

Mar. 31, 2013

Aug. 22, 2012

Jan. 31, 2012

Sutter Buttes Llc [Member]

Sutter Lease [Member]

Carlson Lease [Member]

Sacramento Lease [Member]

Office and Laboratory [Member]

acre

Operating Leased Assets [Line Items]

Lease agreement, increased rent, per month

$1,500

$1,000

$500

Land lease agreement, aggregate rent amount

82,300

66,450

1,000

Payments for Rent

250,000

Area of Land

1,000

Operating Leases, Rent Expense

62,500

Due from Related Parties

72,917

Security deposit

2,500

1,500

1,000

Monthly Payments For Rent

$2,300

Lease Agreement Expiry Term

'5 years

'24 months

Lease Agreement Expiry Date

1-Sep-16

COMMITMENTS_Details

COMMITMENTS (Details) (USD $)	6 Months Ended
COMMITMENTS (Details) (USD $)	Sep. 30, 2013
Commitments And Contingencies [Line Items]	'
Initial Term Of Patents License Agreement	'10 years
Cash Fees And Payable For Patents License Agreement	$50,000
Cash Paid For Patents License Agreement	37,500
Percentage Of Royalties On Sale Price Of Products	0.50%
Minimum Annual Royalty	10,000
Cash Due Of Patents License Agreement Due In One Year	12,500
Proceeds From Patent Prosecution Cost	$50,000

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)	6 Months Ended		1 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Oct. 31, 2013	Oct. 31, 2013	Oct. 31, 2013
		Stock Incentive Plan 2012 [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
				Stock Incentive Plan 2012 [Member]	Stock Incentive Plan 2012 [Member]
					Consultants [Member]
Subsequent Event [Line Items]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	'	'	'	100,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'31 months	'	'	'3 years
Convertible Notes Payable, Total	'	'	$50,000	'	'
Conversion of Stock, Shares Converted	'	'	111,112	'	'
Conversion Of Stock, Shares Issued	427,778	'	500,000	'	'
Conversion of Stock, Amount Issued	'	'	$170,000	'	'